% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gull:309653,
      author       = {A. Gullà and M. V. Dhodapkar and H. Einsele and M.-S.
                      Raab$^*$ and A. G. Solimando and C. Botta and M. Turi and L.
                      S. Sester and A. J. Portuguese and T. Steinbrunn and K. C.
                      Anderson},
      title        = {{R}ethinking {M}ultiple {M}yeloma {T}reatment: {T}he
                      {B}iological and {C}linical {I}nsights {G}uiding
                      {I}mmune-{B}ased {C}ombinations.},
      journal      = {Blood cancer discovery},
      volume       = {nn},
      issn         = {2643-3230},
      address      = {Philadelphia, PA},
      publisher    = {American Association for Cancer Research},
      reportid     = {DKFZ-2026-00285},
      pages        = {nn},
      year         = {2026},
      note         = {epub},
      abstract     = {The standard of care for multiple myeloma has rapidly
                      evolved to include immune-based therapies. However,
                      achieving durable immune control and long-term survival,
                      particularly in high-risk patients, remains difficult. In
                      this article, we review the immune effects of existing and
                      emerging therapies, dissect key drivers of resistance,
                      highlight rational combinations and treatment-sequencing
                      strategies, and summarize ongoing clinical trials that aim
                      to optimize durable immune control. We discuss how the
                      application of these biological and clinical insights may
                      help us rethink multiple myeloma treatment to fully
                      eradicate residual disease and elicit sustained natural
                      and/or synthetic tumor-specific immunity.Preclinical and
                      clinical insights are reshaping how immune-based therapies
                      are used in multiple myeloma. This review explores how
                      optimizing the integration of natural and synthetic immunity
                      can support a shift from disease control to deep, durable
                      immune eradication, paving the way for personalized immune
                      strategies tailored to individual immune profiles.},
      cin          = {A360},
      ddc          = {610},
      cid          = {I:(DE-He78)A360-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41636424},
      doi          = {10.1158/2643-3230.BCD-25-0107},
      url          = {https://inrepo02.dkfz.de/record/309653},
}